Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ALN-HSD

Phase 2Small molecule

Alnylam Pharmaceuticals

ALN-HSD is one of 79 small molecule programs targeting Hepatitis. It is currently in Phase 2.

3

Indications

2

Total Trials

1

Active Trials

78

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Liver DiseaseActive, not recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Recruiting

HepatitisPhase 1

Active, not recruiting

Liver DiseasePhase 2

Active, not recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2

Recruiting

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

Actos

Cysteine Hydrochloride

Crestor

Aquasol E

NNational Eye Institute (NEI)

Amoxil

GGlobal Antibiotics Research and Development Partnership

Hepatitis B Vaccine

Cervarix

Coenzyme Q10

MMclean Hospital

PI-88

CCellxpert Biotechnology Corp.

Recombinant Hepatitis B Vaccine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT05519475

Clinical

Trials by Indication[1]

Hepatitis1 trial

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Terminated· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 1·NCT04565717·6 enrolled

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT05519475·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALN-HSD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-HSD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-HSD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Alnylam Pharmaceuticals

Related News